OraSure Technologies Q1 revenue declines on lower HCV test sales

OraSure Technologies

06/05/2026 21:37

Overview

US diagnostics test maker's Q1 revenue fell 7% yr/yr, core revenue nearly flat

Gross margin improved to 42.3% from 41.1% a year earlier

Company repurchased $5 mln in stock during the quarter

Outlook

OraSure Technologies guides Q2 2026 total revenues of $27 mln to $30 mln

Company says it is focused on leveraging manufacturing capabilities to drive operating efficiencies

OraSure says it is positioned for growth as regulatory and commercial milestones approach in 2026

Result Drivers

DIAGNOSTICS REVENUE DECLINE - Lower HCV test sales contributed to a 5% drop in diagnostics revenue

GROSS MARGIN EXPANSION - Gross margin improved due to focus on manufacturing capabilities and operating efficiencies, per CEO Carrie Eglinton Manner

Company press release: ID:nGNX47cnn9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Beat*
$27.9 mln
$27.71 mln (2 Analysts)
Q1 Gross Margin
42.30%
Q1 Adjusted Operating Income
Miss
-$19 mln
-$15.86 mln (2 Analysts)
Q1 Operating Income
-$23.3 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OraSure Technologies Inc is $4.00, about 33.3% above its May 5 closing price of $3.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)